Gillian Ellison

Summary

Affiliation: AstraZeneca R and D

Publications

  1. pmc EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
    Gillian Ellison
    AstraZeneca, Macclesfield, Alderley Park, UK
    J Clin Pathol 66:79-89. 2013
  2. pmc A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
    Gillian Ellison
    AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK
    J Exp Clin Cancer Res 29:132. 2010
  3. pmc Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
    Jonathan R Dry
    Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
    Cancer Res 70:2264-73. 2010

Detail Information

Publications3

  1. pmc EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
    Gillian Ellison
    AstraZeneca, Macclesfield, Alderley Park, UK
    J Clin Pathol 66:79-89. 2013
    ..We also evaluated data on the use of cytology samples in order to determine their suitability for EGFR mutation analysis...
  2. pmc A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
    Gillian Ellison
    AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK
    J Exp Clin Cancer Res 29:132. 2010
    ..We have compared mutation analysis by DNA sequencing and Amplification Refractory Mutation System™ (ARMS™) for their ability to detect mutations in clinical biopsy specimens...
  3. pmc Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
    Jonathan R Dry
    Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
    Cancer Res 70:2264-73. 2010
    ..These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies...